The effects of gender affirming hormone therapy on skeletal muscle training and epigenetics

Not Applicable

• Conditions: muscle health and performance; body composition; metabolic health; gender dysphoria; Musculoskeletal - Normal musculoskeletal and cartilage development and function; Metabolic and Endocrine - Other endocrine disorders

• Registration Number: ACTRN12621001415897
• Lead Sponsor: Victoria University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2021-10-20
• Last Update Posted: 6 December 2021

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 160

Inclusion Criteria

For participants commencing gender affirming hormone therapy:
•Adults aged 18 years and over.
•Willingness to consent and comply with study requirements
•Diagnosed with gender dysphoria who are about to commence gender affirming hormone therapy

For matched cisgender participants:
•Adults aged 18 years and over.
•Willingness to consent and comply with study requirements
•Age-matched to participating individual about to commence gender affirming hormone therapy

Exclusion Criteria

•Prior use of gender affirming hormone therapy.
•Prior hypogonadism including previous oophorectomy or orchidectomy.
•Past medical history of cardiovascular conditions, dizziness or fainting during exertion, significant chronic or recurrent respiratory condition, significant neuromuscular, major musculoskeletal problems interfering with ability to cycle, uncontrolled endocrine and metabolic disorders or diabetes requiring insulin and other therapies, infectious blood borne disease, disorders or use of medications that will affect blood clotting and allergies to anaesthetic.
•Active cigarette use.
•Language difficulties.

Study & Design

• Study Type: Observational
• Study Design: Not specified